Bicara Therapeutics Stock

www.bicara.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $355.03MM

Bicara Therapeutics, founded in 2020, is a clinical-stage company striving to develop biologics for cancer patient treatments. Bicara uses tumor-targeting antibodies and the tumor-microenvironment aiming to impact the tumor site for a hardwearing effect. Working to advance cancer treatment for patients who have had difficulty with first- and second-line therapies, Bicara partners with chemistry, manufacturing, and controls (CMC) experts and professional protein engineers who have a history of progressing FDA-approved drugs. Bicara Therapeutics is headquartered in Cambridge, Massachusetts.

Register To Buy and Sell Shares

For more details on financing and valuation for Bicara Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Bicara Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Bicara Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Claire Mazumdar Ph.D
Chief Executive Officer
Ryan Cohlhepp Ph.D
Chief Operating Officer & President
Ivan Hyep
Chief Financial Officer
David Raben MD
Chief Medical Officer

Board Members

Carolyn Ng Ph.D
TPG
Heath Lukatch Ph.D
Red Tree Venture Capital
Jake Simson Ph.D
RA Capital Management
Ketan Patel MD
F-Prime Capital
Kiran Mazumdar-Shaw
Biocon

Frequently Asked Questions About Bicara Therapeutics’ Stock

plusminus
Can you buy Bicara Therapeutics’ stock?
Bicara Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Bicara Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Bicara Therapeutics’ stock?
Yes, you can sell stock of a private company like Bicara Therapeutics. Forge can help you sell your Bicara Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Bicara Therapeutics’ stock price?
Bicara Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Bicara Therapeutics’ private market stock price with Forge Data.
plusminus
What is Bicara Therapeutics’ stock ticker symbol?
Bicara Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Bicara nets second nine-digit haul in nine months, raising $165M series C
Venture capitalists and biotech CEOs have been largely speaking with one voice this year with respect to the state of new financing, underscoring that the only thing that matters is having enough money to last until the next catalyst. Bicara Therapeutics is acting on that advice, closing a $165 million series C just nine months after raising a $108 million series B. The new round is quadruple the $40 million secured by Bicara when it launched in 2021.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.